BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2213 related articles for article (PubMed ID: 18555941)

  • 1. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
    Brams M; Mao AR; Doyle RL
    Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
    McGough JJ; Pataki CS; Suddath R
    Expert Rev Neurother; 2005 Jul; 5(4):437-41. PubMed ID: 16026226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
    Boellner SW; Stark JG; Krishnan S; Zhang Y
    Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
    Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.
    McGough JJ; Biederman J; Wigal SB; Lopez FA; McCracken JT; Spencer T; Zhang Y; Tulloch SJ
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):530-8. PubMed ID: 15908835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
    Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.
    Wilens T; Pelham W; Stein M; Conners CK; Abikoff H; Atkins M; August G; Greenhill L; McBurnett K; Palumbo D; Swanson J; Wolraich M
    J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):424-33. PubMed ID: 12649629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A community assessment, open-label study of the safety, tolerability, and effectiveness of mixed amphetamine salts extended release in school-age children with ADHD.
    Ambrosini PJ; Sallee FR; Lopez FA; Shi L; Michaels MA;
    Curr Med Res Opin; 2006 Feb; 22(2):427-40. PubMed ID: 16466615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
    Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulant dosing for children with ADHD: a medical claims analysis.
    Olfson M; Marcus S; Wan G
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):51-9. PubMed ID: 19218896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 111.